Detailed, large-scale investigations have focused on the inhibitory effectiveness of HDACis and HATis in tumor metastasis; however, although site-specific or other acylation modifications have specific functions during tumor metastasis, most reported HDACis and HATis have a broad range of targets. The gene discussed is DPP9; the disease is neoplasm.